This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Mylan Commemorates 24th World AIDS Day

PITTSBURGH, Dec. 1, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today joins communities around the world to commemorate the 24th World AIDS Day by honoring those who have battled HIV/AIDS, celebrating the progress achieved to date in the global response to the disease, and reaffirming Mylan's passionate commitment to the ongoing fight against HIV/AIDS.

Mylan CEO Heather Bresch said, "Mylan is dedicated to expanding access to high quality antiretroviral medications (ARVs) for those in need. On this 24th World AIDS Day, we stand ready to continue contributing to the fight against HIV/AIDS in 2013 and beyond, and believe that an AIDS-free generation is within our grasp."

Mylan continues to support the pledge the U.S. government made on World AIDS Day 2011 to provide treatment to 6 million people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) by the end of 2013. PEPFAR was established in 2003 to help save those suffering from HIV/AIDS around the world. To date, the program has helped 4.5 million people in resource-limited areas receive treatment.

Mylan also continues to support the United Nations' "15 by 15" goal. If met, by 2015 the 15 million people who, according to the World Health Organization's (WHO) 2010 ARV Treatment Guidelines, need antiretroviral therapy would be receiving it.

In order to increase and expand access to ARV medications used to treat HIV/AIDS, Mylan believes it is imperative to focus on enhancing mobility and supply-chain management. As a company with a proven track record for exemplary supply-chain management, Mylan is confident its insights can help shape the global community's efforts to improve access to this vital medicine.

Bresch continued, "We are doing all we can to expand access to life-saving ARVs by scaling up to meet unmet needs and breaking down barriers that stand in the way of getting medicine to people who need it. For the last decade, Mylan has focused on driving down the costs of ARV medicines. Today, the primary barrier standing between patients and treatment is not the cost of drugs, but inadequate access to them.  Our aim is to do for access what we already have done for affordability."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs